Announcements Trials
Browse Landscape

Phase

Phase 3 6Phase 2 5Phase 1 4Phase 2/3 2Phase 1/2 1

Status

Recruiting 2

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Carcinoma, Non-Small-Cell Lung 10Squamous Cell Carcinoma of Head and Neck 8Neoplasms 6Stomach Neoplasms 5Prostatic Neoplasms 5Lung Neoplasms 5Head and Neck Neoplasms 5Oropharyngeal Neoplasms 4Lymphoma, Large B-Cell, Diffuse 4Fatigue 4Urinary Bladder Neoplasms 3Recurrence 3Ovarian Neoplasms 3Neoplasm Metastasis 3Myasthenia Gravis 3Mouth Neoplasms 3Leukemia, Myeloid, Acute 3Colorectal Neoplasms 3Weight Loss 2Peritoneal Neoplasms 2Pancreatic Neoplasms 2Nasopharyngeal Carcinoma 2Melanoma 2Laryngeal Neoplasms 2Hypopharyngeal Neoplasms 2Glioblastoma 2Fallopian Tube Neoplasms 2Colonic Neoplasms 2Cholangiocarcinoma 2Carcinoma, Squamous Cell 2

Interventions

Nivolumab 2Taxes 1Specimen Handling 1Ramucirumab 1Paclitaxel 1Magnetic Resonance Spectroscopy 1Folfox protocol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2/3 × Adenocarcinoma Of Esophagus × 30 days × Clear all
NCT06203600 2026-05-26

Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial

National Cancer Institute (NCI)

Phase 2/3 Recruiting
224 enrolled
Gastrointestinal

Adenocarcinoma Of Esophagus

NCT07221149 2026-05-14

A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)

Bristol-Myers Squibb

Phase 2/3 Recruiting
690 enrolled
Gastrointestinal

Adenocarcinoma Of Esophagus, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡